Trending News Today: Potential Eculizumab Biosimilar Shows Bioequivalence in Study

Amgen’s ABP 959 demonstrated bioequivalence to its reference product eculizumab (Soliris, Alexion) in a phase 1 trial, The Center for Biosimilars reported. According to the article, the trial included 219 healthy volunteers randomized to receive a 300-mg intravenous infusion of either the proposed biosimilar, the European Union reference, or the US reference. Overall, the geometric mean ratios of pharmacokinetic and pharmacodynamic parameters after a single infusion were similar among all 3 groups, the article reported.
A new study found that common pain medications called gabapentinoids, which include pregabalin and gabapentin, may increase users’ risks for suicidal behavior, unintentional overdose, injuries, and car accidents, Reuters reported. According to the article, the researchers examined data on 191,973 individuals prescribed pregabalin or gabapentin from 2006 to 2013. Overall, compared with patients who weren’t taking a gabapentinoid drug, the risk while taking pregabalin or gabapentin was 26% higher for suicidal behavior or suicide, 24% higher for accidental overdose, 22% higher for head or body injuries, and 13% higher for car crashes and traffic offenses, the article reported.
A new survey from WebMD and the University of Pittsburgh Medical Center looked at public knowledge and attitudes about the safety and efficacy of liver transplants from living donors, The Hill reported. According to the article, 68% of survey respondents said they were not knowledgeable about liver disease and approximately 80% had little knowledge of the liver transplant process. Additionally, 43% of respondents thought liver transplants were mostly needed because of drug or alcohol abuse, the article reported.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

Top news of the day from across the health care landscape.
Top news of the day from across the health care landscape.
Top news of the day from across the health care landscape.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.